title: Quantification of fluid resorption from diabetic macular oedema with foveal serous detachment after dexamethasone intravitreal implant (Ozurdex®) in a pregnant diabetic.
abstract: OBJECTIVE
  To quantify the fluid resorption from the centre of the fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after the administration of intravitreal dexamethasone implant (Ozurdex®).
  
  
  METHODS
  A 36-year-old pregnant woman with type 1 diabetes for 33 years presented with diabetic macular oedema with foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) in Snellen notation and central retinal volume assessed by optical coherence tomography (OCT, Topcon Corporation) were measured almost on a daily basis the first five weeks after implantation and then 2-3 times per month until childbirth.
  
  
  RESULTS
  The pretreatment BCVA was 0.6/1.0, and pretreatment central retinal volume was 0.32 mm3. Near elimination of the oedema was achieved 3 days after treatment. One week after treatment, BCVA improved to preconception level, and full regression of the oedema was achieved. The rate of fluid resorption from the centre of the fovea was highest 3 days after treatment 0.00139 μL/hr and decreasing to 0.00065 μL/hr 1 week after treatment.
  
  
  CONCLUSIONS
  Intravitreal dexamethasone implant Ozurdex reduces promptly central retinal volume in diabetic macular oedema involving the centre of the fovea in pregnancy with highest rate of fluid resorption 3 days after treatment initiation.
authors: Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors: Delila
authors: D
authors: Hodzic-Hadzibegovic
authors: Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors: Shakoor
authors: S
authors: Ba-Ali
authors: Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.|Steno Diabetes Center, Gentofte, Denmark.
authors: Marianne
authors: M
authors: Valerius
authors: Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.|Steno Diabetes Center, Gentofte, Denmark.
authors: Henrik
authors: H
authors: Lund-Andersen
mesh_terms: D000328:Adult; D003907:Dexamethasone / Q000008:administration & dosage*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000150:complications* / Q000188:drug therapy; D004343:Drug Implants; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011247:Pregnancy; D011254:Pregnancy in Diabetics; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone
keywords: best-corrected visual acuity; central retinal volume; diabetic macular oedema; fluid resorption; ozurdex; pregnancy